We use cookies to help us improve the website and your experience using it. You may delete and block all cookies from this site at any time. However, please note this may result in parts of the site no longer working correctly. If you continue without changing your settings we will assume you are happy to receive all cookies on this site.

Close

Central Manchester Hospitals support MSP acquisition of Alderley Park

The new owners of Alderley Park shared their vision for the future of AstraZeneca's former R&D site at the celebratory launch event on 9th May 2014 held at the Cheshire site. Manchester Science Parks (MSP) shareholders were joined by local, regional and national business and community leaders.

Manchester Science Parks, who with majority shareholder Bruntwood acquired the 400 acre site in March, revealed its ambition to maintain top quality bioscience as the cornerstone of its commercial strategy. MSP praised the investment record of previous owners AstraZeneca, and set out how the state-of-the-art research facilities at the site will  be adapted to a new business model, where a vibrant community of businesses would specialise in different aspects of the drug discovery chain, working in a campus environment to encourage collaboration and the sharing of risk.

MSP, which with property partner Bruntwood, has a long track record of creating inspiring places for business success, also shared its vision for the 400 acre site in the heart of the Cheshire countryside. The new owner emphasised the importance of putting people at the heart of the Park, and of creating a place of beauty which nurtures creativity and helps businesses balance the pressures of working life with the promotion of well-being, leisure, and pleasure.

Chris Oglesby, Bruntwood CEO and MSP Chairman, said:

"Through our acquisition of Alderley Park, we have a unique opportunity to create a diverse innovative community of bioscience businesses which is internationally respected for the quality of its work and as a sustainable business model. With our partners and the community of exceptional scientists who choose to remain at the Park, we will build a flagship for a vibrant life sciences industry in the North of England"

The vision for Alderley Park to remain at the forefront of bioscience innovation is supported  by MSP's public sector and academic partners, including the two Manchester universities, Manchester, Salford and Cheshire East Councils, and the Central Manchester University Hospitals NHS Foundation Trust. All partners are united in working together to develop a bioscience business cluster at the site that could establish Alderley Park as an internationally recognised centre of scientific excellence at the heart of the North West.

Professor Dame Nancy Rothwell, President and Vice Chancellor, The University of Manchester, commented:

"I am delighted to see the progress that has been made in ensuring the future of Alderley Park as a site of outstanding science. This has been achieved through excellent collaboration between the partners who are here today."

Former owners of the site, AstraZeneca, will continue to have a long-term presence at Alderley Park, with over 700 employees retained on site, and will assist MSP in delivering its vision by supporting start-up and growing smaller life science businesses. AstraZeneca is committed to ensuring its legacy continues and has pledged a £5m contribution to the 'Alderley Park Springboard Fund' that will be used to support new businesses starting up at Alderley Park. MSP will also contribute £5m to the new Fund, and is optimistic that further contributions will ensure that it can play an important role in retaining and nurturing talent and enterprise at Alderley Park.

Mene Pangalos, Executive Vice President Innovative Medicines and Early Development, AstraZeneca, stated:

"As we handover ownership of Alderley Park, we can look back with pride on the important role the site has played in our success. We are delighted that our legacy of scientific innovation stretching back many decades will be built upon by Manchester Science Parks, helping ensure the UK remains a global leader in life sciences."

The launch event provided an opportunity for attendees to gain an insight into the discussions around the exciting vision for the future of Alderley Park. Chaired by Chris Oglesby, Bruntwood CEO and MSP Chairman, the event brought together a high profile delegation of representatives from MSP, Bruntwood, The University of Manchester, Cheshire East Council and AstraZeneca, including the Right Honourable George Osborne MP as keynote speaker.

As Chancellor of the Exchequer and the local Member of Parliament for Tatton, Mr Osborne explained the Government's commitment to Alderley Park and the importance of securing the future of the site. The new state-of-the-art science hub will form an integral part of an ambitious global Life Science Strategy for the UK, as well as act as a driver for a single health science strategy for the North West region and beyond.

At the launch event, Mr Obsorne presided over the handing over of Alderley Park from Mene Pangalos, Executive Vice President Innovative Medicines and Early Development at AstraZeneca to Chris Oglesby, Bruntwood CEO and MSP Chairman. This symbolic event marks the start of the transformation of Alderley Park by its new owners, Manchester Science Parks.

 

Notes to Editors

About Manchester Science Parks

A Greater Manchester based public-private partnership and science park operator, MSP has over 30 years' experience in creating the right environments for innovation. MSP has a track record of supporting the growth of companies in the biomedical, ICT, industrial technologies and digital media sectors, ranging in size from start-ups to international centres of R&D excellence.

MSP's shareholders are Bruntwood Ltd, The University of Manchester, Manchester Metropolitan University, and Manchester and Salford City councils. The acquisition is funded by Bruntwood, MSP and Cheshire East Council, with Bruntwood as the majority funder. For more information, please visit: www.manchesterscienceparks.co.uk

 

About Bruntwood

Bruntwood is a family-owned and run property company whose goal is to create the right places for businesses to succeed. With over 109 office buildings across Manchester, Liverpool, Leeds and Birmingham, Bruntwood specialises in providing bespoke workspace from one desk for a day through to a whole building for 25 years.

Over the company's 36-year history they have developed a proven business model that is based on the innovative development of commercial buildings combined with a single-minded focus on the needs of their customers. In 2012, Bruntwood applied this model to Manchester Science Parks (MSP) when they took a majority share in the site. Each year Bruntwood and the Oglesby family shareholders donate a figure in excess of 10% of profits to art and charity initiatives that make a difference to the cities they operate in. For further information, please visit: bruntwood.co.uk

 

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit: www.astrazeneca.com

For media enquiries please contact:

 

Jackie Nally

Lexington Communications

T: 0161 711 0305 / 07921000775

E: jackie.nally@lexcomm.co.uk